Focus on Minimizing Toxicity and Biomarker Identification by 2025
By 2025, Immunotherapy Progress will be focused on two key areas: minimizing the unique spectrum of side effects associated with immune-targeted drugs and identifying reliable biomarkers that predict response. Unlike the adverse events from kinase inhibitors, immune-related side effects require distinct management protocols. Furthermore, researchers are urgently seeking a predictive biomarker...
0 Kommentare 0 Anteile 5 Ansichten 0 Vorschau